Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hydromorphone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Buprenorphine 0.15 MG | DRUG | given every 15 minutes as needed for numerical pain score 4 or greater for a maximum of three doses |
| Hydromorphone 0.25 mg IV | DRUG | given every 15 minutes as needed for numerical pain score 4 or greater for a maximum of three doses |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 23 | N/A | Undisclosed |
| Stryker Corporation | SYK | 4 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | N/A | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | - | Undisclosed |
| Cooper Companies, Inc. | COO | 1 | - | Undisclosed |
Hydromorphone is being studied for use in Fracture, specifically for analgesia in older adults with acute fractures in the emergency department. It is currently in Phase 2 clinical development as a small molecule treatment for this musculoskeletal condition.
Hydromorphone is being developed by The Cooper Companies, Inc., which trades under the ticker COO. The company is conducting clinical research on this small molecule for the treatment of fracture-related pain.
Hydromorphone is in Phase 2 clinical development for the treatment of fracture. It is an investigational drug and has not been approved by regulatory authorities. One active clinical trial is currently listed for this indication.
Hydromorphone is being evaluated in clinical trial NCT07430345, titled 'Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study.' This trial is in Phase 1/Phase 2 and is not yet recruiting, with an estimated enrollment of 48 participants.
No, Hydromorphone is not the same as Buprenorphine. The clinical trial NCT07430345 compares these two drugs for analgesia in older adults with acute fractures. Hydromorphone is a separate small molecule being studied for the same condition.